Pharmaceutical composition comprising an Antibody that specifically recognizes CD38 and bortezomib.Claim 1: a Pharmaceutical Combination comprising an Antibody that specifically recognizes at least CD38 and bortezomib, in which the Antibody is capable of killing CD38 + cells by apoptosis, Antibody dependent Cell mediated cytotoxicity (ADCC) and citoto Xicidad complement dependent (CDC).Claim 2: The combination of claim 1, in which the Antibody is a Humanized Antibody.Claim 3: The combination of claim 2, in which the Antibody comprising one or more of the complementarity determining regions that have a sequence of amino acids selected from the group consisting of SEQ ID no. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 and 81.Claim 16: An article of manufacture comprising: a) a packaging material, (b) a combination of an Antibody that specifically recognizes at least CD38 and bortezomib, in which the Antibody is capable of killing CD38 + cells by apoptosis, c u00e9l mediated cytotoxicity Ulas Antibody dependent (ADCC) and complement dependent cytotoxicity (CDC)And (c) a Label or Package insert in the packaging material which indicates that the combination of this is effective to treat cancer.Винахід стосується фармацевтичної композиції, що містить антитіло, яке специфічно розпізнає CD38, і бортезоміб.
